Drugmakers Cut Prices 61% to Get on Coveted China List
- Prices are cut an average 61% as China expands drug coverage
- Government adds 70 new drugs to national insurance list
Photographer: Kiyoshi Ota/Bloomberg
This article is for subscribers only.
Drugmakers including AstraZeneca Plc and Roche Holding AG agreed to cut prices of some of their newest innovative drugs in China by an average of 61% as the government expanded the number of treatments covered under national insurance.
Some 70 new therapies were added for coverage by China’s state-run medical insurance fund after months-long negotiations over prices, according to a notice on the National Healthcare Security Administration’s website on Thursday.